Pharmaceutical

Donald Trump has punished European pharmaceutical companies by imposing 100 percent tariffs on their branded products unless they are prepared to set up a manufacturing plants in the US. That is one way of putting it, but why is the issue of tariffs so often seen from the point of view of the producers and so rarely seen from the position of the consumers? Besides punishing drugs companies, the President has also whacked the American public – or at least that section of the population which relies on patented medicines made outside the US. The cost of treatment for many of these patients will soar as a result. Does Trump think that people will somehow fail to realize this?

Somewhere, possibly in the land of big sheds, just off the M1 in Leicestershire, must be a burgeoning NHS surplus store. Its shelves will be groaning with ventilators and testing kits which turned out not to work, surgical gloves, bibs and masks which turned out to be defective – and quite possibly, in months to come, with millions of shots of vaccines which won’t be able to be used. It was announced this morning that the government has signed up for 60 million doses of a vaccine being developed by GSK and Sanofi – although the financial details of the deal were not released. GSK says the vaccine will enter clinical trials this autumn and will – possibly – be ready for manufacture in the second half of 2021.